Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

261. Insulin Resistance and a Long, Strange Trip. (Abstract)

Insulin Resistance and a Long, Strange Trip. 26886417 2016 04 13 2018 12 02 1533-4406 374 14 2016 Apr 07 The New England journal of medicine N. Engl. J. Med. Insulin Resistance and a Long, Strange Trip. 1378-9 10.1056/NEJMe1600962 Semenkovich Clay F CF From the Division of Endocrinology, Metabolism and Lipid Research, Washington University, St. Louis. eng Editorial Comment 2016 02 17 United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Thiazolidinediones AIM IM N Engl J Med (...) . 2016 Apr 7;374(14):1321-31 26886418 Female Fractures, Bone chemically induced Humans Hypoglycemic Agents therapeutic use Insulin Resistance Ischemic Attack, Transient drug therapy Male Myocardial Infarction prevention & control Stroke drug therapy Thiazolidinediones therapeutic use 2016 2 18 6 0 2016 2 18 6 0 2016 4 14 6 0 ppublish 26886417 10.1056/NEJMe1600962

2016 NEJM

262. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. (Abstract)

Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of uncontrolled diabetes that mainly occurs in individuals with autoimmune type 1 diabetes, but it is not uncommon in some people with type 2 diabetes. The treatment of DKA is traditionally accomplished by the administration of intravenous infusion of regular insulin that is initiated in the emergency department and continued in an intensive care unit (...) or a high-dependency unit environment. It is unclear whether people with DKA should be treated with other treatment modalities such as subcutaneous rapid-acting insulin analogues.To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis.We identified eligible trials by searching MEDLINE, PubMed, EMBASE, LILACS, CINAHL, and the Cochrane Library. We searched the trials registers WHO ICTRP Search Portal and ClinicalTrials.gov. The date of last search

2016 Cochrane

263. Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines

Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness (...) and Guidelines Published on: December 10, 2015 Project Number: RC0731-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of insulin pumps versus multiple daily injections for adults with type 1 diabetes? What is the comparative clinical effectiveness of insulin pump models with continuous glucose monitors versus standard insulin pumps for adults with type 1 diabetes? What is the cost-effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

264. The Long Story Short: Optimizing choice and use of insulin needles

The Long Story Short: Optimizing choice and use of insulin needles image/jpeg

2016 RxFiles

265. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 316. 2015 Final publication URL Indexing Status Subject

2016 Health Technology Assessment (HTA) Database.

266. [Insulin degludec (addendum to Commission A15-10)]

[Insulin degludec (addendum to Commission A15-10)] Insulin degludec (addendum zum Auftrag A15-10) [Insulin degludec (addendum to Commission A15-10)] Insulin degludec (addendum zum Auftrag A15-10) [Insulin degludec (addendum to Commission A15-10)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec (addendum zum (...) Auftrag A15-10). [Insulin degludec (addendum to Commission A15-10)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 315. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel

2016 Health Technology Assessment (HTA) Database.

267. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V]

[Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment (...) according to §35a Social Code Book V] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

2016 Health Technology Assessment (HTA) Database.

268. [Insulin degludec/liraglutide (Addendum to Commission A15-15)]

[Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation IQWiG. Insulin degludec/liraglutid (addendum zum Auftrag A15-15). [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 327. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available

2016 Health Technology Assessment (HTA) Database.

269. Insulin glargine (Abasaglar®)

Insulin glargine (Abasaglar®) Insulin glargine (Abasaglar®) Insulin glargine (Abasaglar®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin glargine (Abasaglar®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines (...) Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2307. 2015 Authors' conclusions Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar®

2016 Health Technology Assessment (HTA) Database.

270. Diabetes Technology: Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults

Diabetes Technology: Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults '); '); Diabetes Technology Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Diabetes Technology Guideline Resources Full Guideline: JCEM | September 2016 Anne L. Peters (chair), Andrew J. Ahmann, Tadej Battelino, Alison Evert, Irl B. Hirsch, M. Hassan Murad, William E. Winter, and Howard Wolpert The 2016 guideline (...) on Diabetes Technology addresses: Matching individuals to the best-suited technological solutions for type 1 and type 2 diabetes management Deciding when individuals would benefit from continuous subcutaneous insulin infusion (CSII) and real-time continuous glucose monitoring (RT-CGM) Assessing and re-assessing individual psychological status, self-care behavior, and education and training before and during use to ensure adherence and maximize successful adoption of technology Resources | ENDO 2016

2016 The Endocrine Society

271. Insulin therapy in type 1 diabetes

Insulin therapy in type 1 diabetes Insulin therapy in type 1 diabetes - NICE CKS Share Insulin therapy in type 1 diabetes: Summary Insulin is a polypeptide hormone secreted by pancreatic beta-cells. The role of insulin is to lower blood glucose to prevent hyperglycaemia and its associated complications, including microvascular complications (retinopathy, nephropathy, and neuropathy), macrovascular complications (cardiovascular, cerebrovascular, and peripheral arterial disease), and metabolic (...) complications (diabetic ketoacidosis and dyslipidaemia). In people with type 1 diabetes, autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency. Consequently, insulin therapy is a medical necessity. Three types of insulin are available in the UK: human insulins, human insulin analogues, and animal insulins (rarely used). Insulins are broadly categorized according to their time-action profiles as: Short-acting insulins — these are used to mimic the physiological secretion

2016 NICE Clinical Knowledge Summaries

272. Insulin therapy in type 2 diabetes

Insulin therapy in type 2 diabetes Insulin therapy in type 2 diabetes - NICE CKS Share Insulin therapy in type 2 diabetes: Summary Insulin is a polypeptide hormone secreted by pancreatic beta-cells. The role of insulin is to lower blood glucose to prevent hyperglycaemia and its associated complications, including microvascular complications (retinopathy, nephropathy, and neuropathy), macrovascular complications (cardiovascular, cerebrovascular, and peripheral arterial disease), and metabolic (...) complications (dyslipidaemia and diabetic ketoacidosis). In people with type 2 diabetes, there is a variable combination of increased insulin resistance and progressive loss of pancreatic beta-cell function. Type 2 diabetes is initially managed with lifestyle changes and antidiabetic drugs. However, with time, many people will require insulin therapy as there is insufficient endogenous insulin to maintain adequate glucose control. Three types of insulin are available in the UK: human insulins, human insulin

2016 NICE Clinical Knowledge Summaries

273. Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

2016 Evidence-Based Medicine

274. Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the Pediatric Population

Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the Pediatric Population "Subcutaneous Insulin in the Treatment of Diabetic Ketoacidosis in the " by Lauren A. Ljunghag < > > > > > Title Author Date of Graduation Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Diabetic ketoacidosis or DKA is an acute and fatal disease that is highly prevalent in the pediatric population. The current gold (...) standard of treatment is continuous intravenous regular insulin (CIRI), which requires admission to the intensive care unit (ICU) and is a substantial cost to the patient. Alternate routes of insulin administration, such as subcutaneous (SQ) insulin, do not require ICU admission. If SQ insulin is found to be safe and efficacious for the treatment of DKA, this treatment modality could replace continuous IV regular insulin, and therefore decrease the need for ICU admission and cost of stay. Methods

2016 Pacific University EBM Capstone Project

275. Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus

Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Article

2016 Evidence-Based Medicine

276. Regulation of Insulin and Insulin-Like Activity in Malnourished Patients with Carcinoma Ventriculi Subjected to Total Gastrectomy and Personalized Nutritional Support Full Text available with Trip Pro

Regulation of Insulin and Insulin-Like Activity in Malnourished Patients with Carcinoma Ventriculi Subjected to Total Gastrectomy and Personalized Nutritional Support Insulin and insulin-like growth factor (IGF) activities are disturbed during critical illness. Time-course changes in the concentrations of insulin, IGF-I and IGF-binding proteins (IGFBPs) were monitored in this study and their correlation with interleukin (IL)-6 was assessed in patients subjected to total gastrectomy and specific (...) nutritional regime.Patients were fed post-operatively according to the following scheme: parenteral nutrition on day 1, enteral nutrition combined with parenteral form from day 2 to 7, peroral nutrition from day 8 and full oral nutrition from day 14. Blood samples were taken periodically and the levels of IL-6, insulin, IGF-I and IGFBP-1 to -4 were determined.On day 1 post-operatively, the concentration of IL-6 reached its maximum and decreased afterwards. The concentration of insulin increased until day

2015 Journal of medical biochemistry

277. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. Previous studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes have produced inconclusive results.To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes.Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled (...) randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years (mean [SD] 15.3 [1.7] years) with mean type 1 diabetes duration 7.0 (3.3) years, mean body mass index (BMI) 94th (4) percentile, mean total daily insulin 1.1 (0.2) U/kg, and mean HbA1c 8.8% (0.7%).Randomization to receive metformin (n = 71) (≤2000 mg/d) or placebo (n = 69).Primary outcome was change in HbA1c from baseline to 26 weeks adjusted for baseline HbA1c. Secondary outcomes included change in blinded continuous glucose

2015 JAMA Controlled trial quality: predicted high

278. Insulin glargine (Abasaglar) - for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above

Insulin glargine (Abasaglar) - for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above Final Appraisal Recommendation Advice No: 3715 – November 2015 Tinzaparin sodium (innohep ® Syringe) 20,000 units/ml solution for injection Limited submission by LEO Pharma Additional note(s): • This advice may be considered in conjunction with AWMSG recommendations on the prescribing of low molecular weight heparin in Wales. In reaching the above recommendation AWMSG

2015 All Wales Medicines Strategy Group

279. Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus

Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus Final Appraisal Recommendation Advice No: 2715 – October 2015 Insulin degludec/liraglutide (Xultophy ® ? ) 100 units/3.6 mg per ml solution for injection Submission by Novo Nordisk Ltd Additional note(s): • Insulin degludec/liraglutide (Xultophy ® ? ) should be prescribed by brand name to avoid medication errors. In reaching the above recommendation AWMSG has taken account of the appraisal (...) . Recommendation of AWMSG Insulin degludec/liraglutide (Xultophy ® ? ) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy ® ? ) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec

2015 All Wales Medicines Strategy Group

280. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review Full Text available with Trip Pro

Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review Continuous subcutaneous insulin infusion (CSII) is increasingly used in clinical practice for the management of selected patients with Type 1 diabetes. Several cost-effectiveness studies comparing CSII vs. multiple insulin injections (MDI) have been reported. The aim was systematically to review these analyses and test the hypothesis that CSII

2015 EvidenceUpdates